CR8377A - Derivados de acidos fenoxiaceticos utiles como agonistas dobles de receptor activado por proliferador de peroxisoma - Google Patents

Derivados de acidos fenoxiaceticos utiles como agonistas dobles de receptor activado por proliferador de peroxisoma

Info

Publication number
CR8377A
CR8377A CR8377A CR8377A CR8377A CR 8377 A CR8377 A CR 8377A CR 8377 A CR8377 A CR 8377A CR 8377 A CR8377 A CR 8377A CR 8377 A CR8377 A CR 8377A
Authority
CR
Costa Rica
Prior art keywords
proofisador
peroxisoma
derivatives
useful
phenoxyacetic acids
Prior art date
Application number
CR8377A
Other languages
English (en)
Inventor
Kuo Gee-Hong
Shen Lan
Wang Aihua
Zhang Yan
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR8377A publication Critical patent/CR8377A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/081,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invencion se refiere a acidos fenoxiaceticos y analogos de la formula (I), composiciones que los contienen, y metodos para usarlos como moduladores de PPAR para tratar o inhibir la progresion de, por ejemplo, dislipidemia.
CR8377A 2003-10-31 2006-05-02 Derivados de acidos fenoxiaceticos utiles como agonistas dobles de receptor activado por proliferador de peroxisoma CR8377A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51656103P 2003-10-31 2003-10-31

Publications (1)

Publication Number Publication Date
CR8377A true CR8377A (es) 2008-11-24

Family

ID=34549548

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8377A CR8377A (es) 2003-10-31 2006-05-02 Derivados de acidos fenoxiaceticos utiles como agonistas dobles de receptor activado por proliferador de peroxisoma

Country Status (21)

Country Link
US (3) US7015329B2 (es)
EP (1) EP1684752B1 (es)
JP (1) JP2007527416A (es)
KR (1) KR20060109925A (es)
CN (1) CN1897939A (es)
AR (1) AR046311A1 (es)
AT (1) ATE362367T1 (es)
AU (1) AU2004285530A1 (es)
BR (1) BRPI0416106A (es)
CA (1) CA2544317A1 (es)
CR (1) CR8377A (es)
DE (1) DE602004006529T2 (es)
EA (1) EA009804B1 (es)
EC (1) ECSP066536A (es)
ES (1) ES2287786T3 (es)
IL (1) IL175310A0 (es)
NO (1) NO20062511L (es)
TW (1) TW200528438A (es)
UA (1) UA84035C2 (es)
WO (1) WO2005041959A1 (es)
ZA (1) ZA200604420B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1667964B1 (en) 2003-09-19 2009-07-22 Janssen Pharmaceutica N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
EP1684752B1 (en) * 2003-10-31 2007-05-16 Janssen Pharmaceutica N.V. Phenoxyacetic acids derivatives useful as peroxisome proliferator-activated receptor (ppar) dual agonists
US20080045580A1 (en) * 2004-10-11 2008-02-21 Dr Reddy's Laboratories Limited Novel Isoxazole Compounds Having Ppar Agonist Activity
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
PE20080188A1 (es) 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
JP5864077B2 (ja) 2006-09-08 2016-02-17 ロード アイランド ホスピタル アルコール誘発性肝疾患の治療、予防および回復
US9308198B2 (en) 2006-09-08 2016-04-12 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced brain disease
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP3053440B1 (en) 2007-04-11 2020-08-12 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
ES2423793T3 (es) 2008-05-26 2013-09-24 Genfit Compuestos agonistas de PPAR, preparación y usos para el tratamiento de la diabetes y/o dislipidemias
JP5996532B2 (ja) 2010-07-15 2016-09-21 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 有害生物防除剤としての新規複素環式化合物
JP2013538215A (ja) 2010-08-31 2013-10-10 エスエヌユー アールアンドディービー ファウンデーション PPARδアゴニストの胎児再プログラミング用途
WO2012052412A1 (de) 2010-10-22 2012-04-26 Bayer Cropscience Ag Neue heterocylische verbindungen als schädlingsbekämpfungsmittel
WO2013163248A1 (en) 2012-04-26 2013-10-31 Bristol-Myers Squibb Company Par4 agonist peptides
KR20200127273A (ko) 2012-04-26 2020-11-10 브리스톨-마이어스 스큅 컴퍼니 혈소판 응집을 치료하기 위한 프로테아제 활성화 수용체 4 (par4) 억제제로서의 이미다조티아디아졸 및 이미다조피라진 유도체
WO2024153134A1 (zh) * 2023-01-18 2024-07-25 哈尔滨三联药业股份有限公司 五元杂环类化合物及其医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046232A1 (fr) * 1998-03-10 1999-09-16 Ono Pharmaceutical Co., Ltd. Derives d'acide carboxylique et medicaments contenant ces derives comme principe actif
US6242493B1 (en) * 1998-03-13 2001-06-05 Merck Frosst Canada & Co. Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
WO1999065881A1 (en) 1998-06-19 1999-12-23 Nissan Chemical Industries, Ltd. Heterocyclic compounds as hypoglycemic agents
AUPP609198A0 (en) 1998-09-22 1998-10-15 Curtin University Of Technology Use of non-peptidyl compounds for the treatment of insulin related ailments
JP2002543065A (ja) 1999-04-28 2002-12-17 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ppap受容体リガンドとしてのトリアリール酸誘導体
EP1177187B1 (en) 1999-04-28 2007-07-25 Sanofi-Aventis Deutschland GmbH Di-aryl acid derivatives as ppar receptor ligands
JP2003508389A (ja) * 1999-08-27 2003-03-04 エリ リリー アンド カンパニー ビアリール−オキサ(チア)ゾール誘導体およびそのpparモジュレーターとしての使用
JP4790969B2 (ja) * 2000-08-11 2011-10-12 日本ケミファ株式会社 ペルオキシソーム増殖剤応答性受容体δの活性化剤
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
DE60336264D1 (de) 2002-12-20 2011-04-14 Bayer Pharmaceuticals Corp Indanessigsäure-derivate und ihre verwendung als pharmazeutische mittel sowie zwischenprodukte und methoden zu ihrer herstellung
EP1684752B1 (en) * 2003-10-31 2007-05-16 Janssen Pharmaceutica N.V. Phenoxyacetic acids derivatives useful as peroxisome proliferator-activated receptor (ppar) dual agonists

Also Published As

Publication number Publication date
US7498351B2 (en) 2009-03-03
IL175310A0 (en) 2006-09-05
ES2287786T3 (es) 2007-12-16
US20090131489A1 (en) 2009-05-21
TW200528438A (en) 2005-09-01
UA84035C2 (ru) 2008-09-10
ECSP066536A (es) 2006-12-20
US20060074246A1 (en) 2006-04-06
AR046311A1 (es) 2005-11-30
EA009804B1 (ru) 2008-04-28
JP2007527416A (ja) 2007-09-27
CA2544317A1 (en) 2005-05-12
EP1684752B1 (en) 2007-05-16
BRPI0416106A (pt) 2007-01-02
DE602004006529T2 (de) 2008-01-31
WO2005041959A1 (en) 2005-05-12
NO20062511L (no) 2006-07-27
EA200600878A1 (ru) 2006-10-27
CN1897939A (zh) 2007-01-17
EP1684752A1 (en) 2006-08-02
US20050096362A1 (en) 2005-05-05
US7015329B2 (en) 2006-03-21
ATE362367T1 (de) 2007-06-15
KR20060109925A (ko) 2006-10-23
AU2004285530A1 (en) 2005-05-12
DE602004006529D1 (de) 2007-06-28
ZA200604420B (en) 2007-10-31

Similar Documents

Publication Publication Date Title
CR8377A (es) Derivados de acidos fenoxiaceticos utiles como agonistas dobles de receptor activado por proliferador de peroxisoma
ECSP066434A (es) Acidos 4-((fenoxialquil)tio)-fenoxiaceticos y analogos
ECSP088590A (es) Derivados de aminoácido multicíclicos y sus métodos de uso
UY30511A1 (es) Agonistas de ep2
AR053334A1 (es) Pirazolilcarboxanilidas
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
ECSP077319A (es) Acidos 4-((fenoxialquil)tio)-fenoxiaceticos, y analogos de los mismos
NI200900093A (es) Compuestos que modulan la actividad de c-fms y/o c-kit y uso de los mismos.
PA8693101A1 (es) Compuestos de isoindol-imida y composiciones que los incluyen y mètodos para su uso
CR11522A (es) Derivados de alcanos azabiciclicos sustituidos con biarilo como moduladores de la actividad de los receptores nicotinicos de acetilcolina
ECSP11011347A (es) Nicotinamida sustituida como moduladores KCNQ2/3
PA8663501A1 (es) Derivados de indol, benzotiofeno, benzofurano e indeno cicloalquilcondensados
BRPI0518203A2 (pt) mÉtodos para preparaÇço de compostos indazol
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
DOP2006000202A (es) Derivados de carboxamida como antagonistas del receptor muscarinico
CR9786A (es) Compuestos de bencimidazol-tiofeno
UY29343A1 (es) Pirazolopiridinas y sales de las mismas, una composición farmacéutica que comprende dichos compuestos, un método para prepararlos y su uso.
CR7566A (es) Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
UY30627A1 (es) Inhibidores de metaloproteasas derivados de heterociclos
NI200700074A (es) Acidos 4-((fenoxialquil)tio)-fenoxiaceticos y analogos
ECSP066435A (es) Acidos 4-((fenoxialquil)tio)-fenoxiaceticos y analogos
GT200400143A (es) Compuestos
NO20052280L (no) Substituerte tetraliner og indaner og deres anvendelse
DK1893597T3 (da) AMPA-receptorpotentiatorer
EA200801402A1 (ru) Карбаматные соединения в качестве агонистов рецептора 5-нт